| |
Assignment of clinical isolates to AST categories (%)
|
|---|
| |
Q3 2011-Q2 2012 (DIN)
|
Q3 2012-Q2 2013*(EUCAST)
|
|---|
|
Species#/drug
|
S
|
I
|
R
|
S
|
I
|
R
|
|---|
|
E. cloacae
|
n = 77
| |
n = 41
| |
|
ciprofloxacin
|
97
|
0
|
3
|
85*
|
9
|
6
|
|
S. marcescens
|
n = 116
| |
n = 93
| |
|
ciprofloxacin
|
99
|
0
|
1
|
88*
|
9
|
3
|
|
M. morganii
|
n = 107
|
n = 92
|
|
ciprofloxacin
|
97
|
0
|
3
|
82*
|
10
|
8
|
|
C. freundii
|
n = 93
|
n = 89
|
|
pip/taz
|
77
|
4
|
19
|
87*
|
4
|
9
|
|
P. aeruginosa
|
n = 462
|
n = 444
|
|
piperacillin
|
41
|
53
|
7
|
81*
|
3
|
16
|
|
gentamicin
|
55
|
36
|
9
|
92*
|
0
|
8
|
- *Asterisks indicate a significant (p < 0.05) of the number of susceptible isolates according to EUCAST MIC breakpoints compared to DIN.
- #No variation ≥ 10% in the category susceptible was found for E. coli, K. pneumoniae, P. mirabilis, S. maltophilia, A. baumannii, S. aureus, coagulase negative staphylococci, E. feacalis, and E. faecium.
